Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Chohan

Vascular & Interventional Radiology Williamsville, NY Doctor of Osteopathy

NPI 1154764918 CMS profile 1164979

111 N Maplemere Rd Ste 120, Williamsville, NY 14221

Open in the dashboard

General payments

$54,061

303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Chohan of Williamsville, NY is reported in the CMS Open Payments database as having received $54,061 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $774 16
2024 General $29,058 77
2023 General $7,953 93
2022 General $10,254 33
2021 General $3,244 43
2020 General $464 18
2019 General $2,314 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Chohan
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Omar Chohan were reported at $774. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Omar Chohan Vascular & Interventional Radiology median Middle half National median
2019 $2,314 $422 $125–$1,555 $163
2020 $464 $200 $68–$652 $114
2021 $3,244 $280 $99–$866 $132
2022 $10,254 $433 $137–$1,497 $149
2023 $7,953 $506 $152–$2,019 $160
2024 $29,058 $556 $175–$1,930 $164
2025 $774 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Okami Medical, Inc. $16,197 43 payments
  2. Penumbra, Inc. $15,960 38 payments
  3. Contego Medical, Inc $10,089 6 payments
  4. Inari Medical, Inc. $2,890 18 payments
  5. Argon Medical Devices, Inc. $1,683 3 payments
  6. EKOS Corporation $1,334 4 payments
  7. Abbott Laboratories $736 4 payments
  8. Sirtex Medical Inc $676 24 payments
  9. Medtronic, Inc. $667 20 payments
  10. Surefire Medical, Inc. $617 52 payments
  11. Other $3,212 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $25,525 14 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,513 5 payments
  3. Food and Beverage $9,786 263 payments
  4. Travel and Lodging $8,115 20 payments
  5. Gift $123 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $12,480 30 payments
  2. LOBO LOBO Vascular Occlusion System $12,065 34 payments
  3. LOBO Peripheral Vascular Intervention $4,395 10 payments
  4. RUBY Coil $3,121 4 payments
  5. FLOWTRIEVER CATHETER, S $2,889 18 payments
  6. CT THROMBECTOMY SYSTEM KIT $2,848 16 payments
  7. CLEANER $1,683 3 payments
  8. EKOSONIC $1,334 4 payments
  9. TRINAV INFUSION SYSTEM $617 52 payments
  10. OMNILINK ELITE $525 1 payment
  11. Other $4,975 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 257 billing codes

Paid by Medicare

$148,218

Of which drugs: $724

Medicare patients

2,257

Average age 73

Services billed

6,932

1,217 women, 1,040 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 42%
Ischemic heart disease 41%
Diabetes 40%
Heart failure 36%
COPD 34%
Depression 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadobenate dimeglumine (multihance), per ml A9577 Office 34 533 $418
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 33 2,797 $302

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record